insights_auto
Why is AZN up 3.99%?
Dive Deeperchevron_right
AZN:NYSE
AstraZeneca PLC (US)
$162.03
arrow_upward
+3.99%(+6.21) 1D
$162.03
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 14, 4:00:02 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AZN...
Open
$158.71
High
$162.71
Low
$158.31
Mkt. cap
254.26B
Avg. vol.
2.91M
Volume
3.33M
Dividend
1.99%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
24.22
52-wk high
$212.71
52-wk low
$80.48
EPS
$6.69
Beta
0.30
Shares outstanding
1.55B
No. of employees
96K
Open
$158.71
High
$162.71
Low
$158.31
Mkt. cap
254.26B
Avg. vol.
2.91M
Volume
3.33M
Dividend
1.99%
Quarterly dividend
$0.81
Ex-dividend date
Aug 6, 2026
P/E ratio
24.22
52-wk high
$212.71
52-wk low
$80.48
EPS
$6.69
Beta
0.30
Shares outstanding
1.55B
No. of employees
96K
News stories
From web sources and news partners
Yahoo Finance Australia
·
1 hour ago
Top Research Reports for Mastercard, AstraZeneca & Sandisk
Timothy Sykes
·
3 hours ago
AstraZeneca PLC Stock Gains Favor As Oncology Deals Mount
TipRanks
·
5 hours ago
AstraZeneca’s LAZURE Trial Signals Next Step in Cholesterol Treatment
StocksToTrade
·
5 hours ago
AstraZeneca PLC Stock Draws Upgrades As Oncology Deals Accelerate
Profile
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
About AstraZeneca PLC (US)
CEOPascal Soriot
Employees96.1K
FoundedApr 6, 1999
HeadquartersCambridge, Cambridgeshire, United Kingdom
SectorPharmaceutical industry
Websiteastrazeneca.com